Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EPI-7386 |
Synonyms | |
Therapy Description |
EPI-7386 is an N-terminal domain AR inhibitor that blocks transcriptional activity of both full-length and splice variants of AR, potentially leading to antitumor effects (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B117). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EPI-7386 | EPI7386|EPI 7386 | Hormone - Anti-androgens 54 | EPI-7386 is an N-terminal domain AR inhibitor that blocks transcriptional activity of both full-length and splice variants of AR, potentially leading to antitumor effects (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B117). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04421222 | Phase I | EPI-7386 | Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer (EPI-7386) | Active, not recruiting | USA | CAN | 0 |